


# In response to a growing demand for flexibility and convenience.



Genotropin™ (somatotropin (rbe)) is available in a 12 IU Multidose vial. Once reconstituted Genotropin 12 IU Multidose can be stored in a refrigerator for up to two weeks. This makes the use of individually titrated dosage regimens a practical proposition and reduces the time spent preparing injections. The combination of authentic sequence growth hormone and multidose™ presentation makes the introduction of Genotropin 12 IU Multidose a significant development for patients requiring growth hormone therapy.

## Genotropin™ 12 IU Multidose somatotropin (rbe)

**PRESCRIBING INFORMATION** ▼ **Presentation** A vial of sterile lyophilised powder containing 12 IU somatotropin (rbe) supplied with 3 ml of Water for Injections with 0.25% m-cresol for reconstitution. **Indications** The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. **Reconstitution** Add 3 ml of Water for Injections with 0.25% m-cresol to the lyophilised powder in the vial. Dissolve the drug gently without shaking vigorously. **Dosage and Administration** Administer by subcutaneous or intramuscular injection. Generally a dose of 0.5 - 0.7 IU/kg body weight per week is recommended divided into six or seven subcutaneous injections. Alternatively two to three intramuscular injections can be given. **Contra-Indications** Only patients with unfused epiphyses should be treated. **Precautions** Patients with diabetes mellitus may require adjustment of their antidiabetic therapy. Patients treated with Genotropin should be regularly assessed by a child growth specialist. If given subcutaneously, the injection site should be rotated to prevent lipoatrophy. **Pregnancy and Lactation** In the event of pregnancy occurring during Genotropin therapy, treatment should be discontinued. No information is available as to whether peptide hormones pass into breast milk. **Side-Effects** A few children developed transient local skin reactions during clinical trials. Some patients develop antibodies to growth hormone although the frequency with Genotropin has been low in clinical trials. **Pharmaceutical Precautions** Store between 2-8°C and protect from light. Reconstituted Genotropin 12 IU Multidose may be stored for up to 2 weeks in the refrigerator. **Legal Category** POM. **Package Quantities** Combined pack containing one vial of somatotropin (rbe) 12 IU and one vial of Water for Injections with 0.25% m-cresol. **Product Licence Numbers** Genotropin 12 IU Multidose PL 0022/0079. Water for Injections with 0.25% m-cresol PL 0022/0081. **Price** NHS Price £91.50. **Product Licence Holder** KabiVitrum Ltd, KabiVitrum House, Riverside Way, Uxbridge, Middlesex UB8 2YF. Further information is available on request from the product licence holder.

**Roberto Burgio**  
On the occasion of his 70th birthday 487

### Review

**Rational pharmacotherapy of gastrointestinal motility disorders**  
P. Demol, H.-J. Ruoff, T. R. Wehrhach 489

### Gastroenterology/Hepatology

**IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study**  
A. Bürgin-Wolff, R. Berger, H. Gaze, H. Huber, M. J. Lentze, D. Nusslé 496

### Hematology/Oncology

**Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children**  
E. A. Liados i Vallory, R. Giro, G. Lenoir, M. Payet, P. Houze, R. Bourdon 503

**Erythropoietic protoporphyria in a child**  
M. PLOTTE, A. Hassoun, A. Bourlond, G. Cornu 507

### Imaging techniques

**Evaluation of vein of Galen arteriovenous malformation in newborns by two dimensional ultrasound, pulsed and colour Doppler method**  
G. Vaksman, E. Decoux, P. Mauran, M. Jardin, C. Rey, C. Dupuis 510

### Immunology/Allergology

**Atypical spondyloarthritis in children: proposed diagnostic criteria**  
A. Hussein, H. Abdul-Khaliq, H. von der Hardt 513

**DiGeorge syndrome with hypogammaglobulinaemia: a patient with excess suppressor T cell activity treated with fetal thymus transplantation**  
M. Mayumi, H. Kimata, Y. Suehiro, S. Hosoi, S. Ito, Y. Kuge, K. Shinomiya, H. Mikawa 518

**Sjogren syndrome in childhood: report of two cases**  
A. Siamopoulou-Mavridou, A. A. Drosos, A. P. Andonopoulos 523

**Crohn disease in systemic lupus erythematosus: a case report**  
M. Nagata, Y. Ogawa, S. Hisano, K. Ueda 525

### Subscription information

Volume 148 (8 issues) will appear in 1989. Information about obtaining back volumes and microform editions available upon request.

**North America.** Annual subscription rate: approx. US \$ 786.00 (single issue price approx. \$ 117.00), including carriage charges. Subscriptions are entered with prepayment only.

### Infectious diseases

**Lyme borreliosis in children. A controlled clinical study based on ELISA values**  
M. Millner, M. G. Schimek, D. Spork, M. Schnizer, G. Stanek 527

**Recurrent ascites in an infant with perinatally acquired cytomegalovirus infection**  
I. Levy, M. Shohat, Y. Levy, G. Alpert, M. Nitzan 531

### Medical genetics

**Mitral valve prolapse in Turner syndrome**  
V. Bastianon, A. M. Pasquino, E. Gigliori, G. Bosco, L. Tebaldi, C. Cives, V. Colloridi 533

### Metabolic diseases

**Biochemical markers of bone turnover, intact serum parathyroid hormone and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment**  
K. Kruse, U. Kracht, K. Wohlfart, U. Kruse 535

**Carbamyl glutamate prevents the potentiation of ammonia toxicity by sodium benzoate**  
J. E. O'Connor, M. Costell, S. Grisolia 540

**Neonatal pyruvate dehydrogenase deficiency with lipote responsive lactic acidemia and hyperammonaemia**  
D. J. Byrd, H.-P. Krohn, L. Winkler, C. Steinborn, M. Hadam, J. Brodehl, D. H. Hunneman 543

**Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease**  
E. Azizi, G. Eshel, M. Aladjem 548

**A neonatal case of apolipoprotein C-II deficiency**  
M. Ohno, S. Ishibashi, K. Nakao, T. Nozue, K. Nonomura, N. Yamada, H. Aburatani, H. Shimano, T. Murase 550

**Study of the bone pathology in early mucopolidosis II (I-cell disease)**  
U. E. Pazzaglia, G. Beluffi, E. Bianchi, A. Castello, A. Coci, A. Marchi 553

**A case of combined Farber and Sandhoff disease**  
Ch. Fusch, R. Huenges, H. W. Moser, A. C. Sewell, W. Roggendorf, B. Kustermann-Kuhn, A. Poulos, W. F. Carey, K. Harzer 558

### Neonatology

**The prevalence of high insertion of scrotum, hydrocele and mobile testis in the newborn infant (36-42 weeks gestation)**  
J. Ben-Ari, P. Merlob, F. Mimouni, O. Rosen, S. H. Reisner 563

**Respiratory and arousal responses to hypoxia in apnoeic infants reinvestigated**  
J. Milerad, T. Hertzberg, G. Wennergren, H. Lagercrantz 565

### Nutrition

**Apple juice, fructose, and chronic nonspecific diarrhoea**  
C. M. F. Kneepkens, C. Jakobs, A. C. Douwes 571

### Pneumology

**The effect of a manometer on the mean airway pressure during hand ventilation, an in vitro study**  
J. Karsdon, T. Stijnen, H. M. Berger 574

**Aminophylline dosage in acute severe asthma**  
J. G. A. Gleeson, J. F. Price 577

### Letters to the editors

**Increase in bone density during testosterone therapy in adolescent hypogonadism**

O. Arisaka, M. Arisaka, A. Hosaka, N. Shimura, K. Yabuta, Y. Kawaguchi 579

**Steroids in pneumocystis carinii pneumonia in HIV seropositive infants**  
A. Plebani, M. Clerici Schoeller, M. C. Pietrogrande, M. Bardare, P. Careddu 579

**Neutropenia in Kawasaki disease**  
T. Hara, Y. Mizuno, K. Ueda, H. Akeda, T. Aoki, S. Honda, Y. Yamaguchi, T. Hosoyamada 580

**Very long chain fatty acids in amniotic fluid from a fetus affected with Zellweger syndrome**  
C. Jakobs, H. ten Brink, R. M. Kok, F. Stellaard, W. J. Kleijer, R. J. A. Wanders, R. B. H. Schutgens 581

**Copper in human fetal tissues**  
P. Kamoun, M. Gonzales, N. Mulliez 581

**Lack of relationship between low serum C4 concentrations and incipient retinopathy or nephropathy in diabetic children**  
H. Dorchy, J. Duchateau 582

**Further observations on serum complement levels in diabetic children**  
F. Chiarelli, A. Verrotti, G. Morgese 583

**Urinary excretion of glycosaminoglycans in neoplastic diseases of children**  
P. Strisciuglio, A. Fiorillo, M. Costabile, T. Montini 584

### Abstracts

**The 66th Annual General Meeting of the Scottish Paediatric Society held in Glasgow, November 28th, 1988**  
585



Springer International

Orders should be addressed to:

Springer-Verlag New York Inc.  
Service Center Secaucus  
44 Hartz Way  
Secaucus, NJ 07094, USA  
Tel. (201) 348-4033  
Telex 023 125 994

**All other countries.** Annual subscription rate: DM 1358.00 plus carriage charges; Federal Republic of Germany: DM 17.98 incl. value added tax; all other countries: DM 34.80 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 76.80, India DM 58.00, Australia/New Zealand DM 86.80. Airmail delivery to all other countries is available upon request. Volume price: DM 1358.00, single issue price: DM 203.70 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag  
Heidelberger Platz 3, D-1000 Berlin 33  
Tel. (0)30/8207-0, Telex 183319

# KANTHAL® BABY WARMER



A soft, warm watermattress is kept at an exact temperature (normally 37° C). It transfers it's warmth very efficiently to the baby via direct contact.

Kanthal Baby Warmer will warm babies from 900 g and keep them warm in a safe and pleasant way.

For further information please contact.

## KANTHAL Medical Heating

Äggelundavägen 2, S-175 62 Järfälla  
Tel. + 46 8-761 75 80, Fax. + 46 8-761 05 52

UK Distributor Kanthal Medical Heating  
Tel 0742-44 60 21

## Endocrinologist

Endocrinologist to serve one year in visiting professor status in the Department of Pediatrics at the Texas Tech School of Medicine in El Paso, Texas.

*The principal duties include:*  
management of the pediatric in-patient and outpatient endocrine services and teaching of residents and medical students.

*For more information or to apply contact:*


**Gilbert A. Handal, M.D.**

Associate Chairman of Pediatrics  
Department of Pediatrics  
Texas Tech University  
Regional Academic Health Center  
4800 Alberta Avenue  
El Paso, Texas 79906  
U.S.A.  
Telephone: (915) 545-6787

# BMJ BOOKS

For a complete  
Catalogue of BMJ  
Books

*Please write to:*  
BRITISH MEDICAL JOURNAL,  
P.O. Box 295,  
London, WC1H 9TE



# Essential Paediatric Dermatology

*Julian Verbov, MD., FRCP., FIBiol.,*


Consultant Paediatric Dermatologist,  
Royal Liverpool Children's Hospital

## Contents

The approach to parent and child: The Newborn: Atopic and other dermatitis: Infections and infestations: Napkin area eruptions and erythematous squamous disorders: Hair and nails: Naevi and nodules: Connective-tissue disorders: Vascular disorders and drug eruptions: Genodermatoses: Non-hereditary bullous diseases and mastocytoses: Acne, trauma, light eruptions and pigmentation disorders: A selection of recommended prescribable proprietary preparations: Useful reading: Index

200 pages. Hardcover 240mm x 160mm. 194 illustrations in full colour. ISBN: 1 85457 000 5. Price £25.00

*'Full marks to Dr. Verbov, who has provided a crisp and lucid text suitable for trainees in medicine, paediatrics, and dermatology. In twelve chapters (starting with The Approach to the Child and Parent) most of the common skin conditions are described and beautifully illustrated in colour. Appendices deal with prescribing in dermatology and offer suggestions for further reading; there is a comprehensive index and each chapter concludes with selected contemporary references.'* **Lancet.**



# Colour Atlas of Paediatric Facial Diagnosis

*Trevor P. Mann, MD., FRCP., DCH.,*  
Honorary Consultant Physician,  
Royal Alexandra Hospital for Sick  
Children, Brighton

This magnificent book demonstrates the methodology of facial diagnosis in children of all ages, including the new born. All common conditions in which facial diagnosis is important are to be found together with many diagnostic rarities.

208 pages. Hardcover. 297mm x 210mm. 425 full colour illustrations. ISBN: 1 85457 001 3. Price £70.00

Order through your usual Bookseller or direct  
from: **Clinical Press**, 15 Bucklands Drive,  
Nailsea, Bristol, BS19 2PH

*Clinical Press*

## Think about it



You make a clinical diagnosis. Do you ever consider the thought processes by which you arrived at it? Medical students and practitioners are often concerned with examples of diagnostic logic, but seldom consider them in the context of a general philosophy. Is diagnostic logic out on a limb, or is it based on the same principles as logic in general?

In *Logic in Medicine* doctors and philosophers combine to provide a coherent system of diagnostic logic with a broader view of the science and art of reasoning.

The abstract theory of theories has highly practical applications, and the authors explore the uses of computer technology and artificial intelligence systems as well as "fuzzy logic," "relevant logic," and the logic of economics and ethics. A book for all who wish to clear their minds of cant.

Price: Inland £5.95; Abroad £7.50  
BMA members: Inland £5.45; Abroad £7.00  
(including postage, by air abroad)  
Payment must be enclosed with order

ORDER YOUR COPY NOW FROM  
British Medical Journal, PO Box 295  
London WC1H 9TE  
or any leading medical bookseller



**PRESCRIBING INFORMATION**

**HUMAN VELOSULIN** (Neutral Insulin Injection, human insulin (emp)). **HUMAN INSULATARD** (Isophane Insulin Injection (NPH), human insulin (emp)). **HUMAN MIXTARD** 30/70 (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)). **HUMAN INITARD** 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection (NPH), human insulin (emp)). **Presentation** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml. vials containing 100 iu/ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin – one mark; Human Insulatard – two marks; Human Mixtard 30/70 – three marks; Human Initard 50/50 – four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human Initard 50/50 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (they must not be given intravenously). Intermixing does not affect the characteristics of any of these insulins. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance rate. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins. **Pharmaceutical Precautions** be used. **Legal Category P. Package Quantities** 10 ml. glass vials. **Basic NHS Price** Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.



Store between 2–8°C, protected from sunlight. Insulin which has been frozen should not be used. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/0033/3132/0040. THE WELLCOME FOUNDATION LTD: Human Velosulin 0003/0211; Human Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. Further information is available on request from either: Nordisk-UK, Nordisk House, East Grinstead (0342) 410373, or Wellcome Medical Division, The Wellcome Foundation, Beckenham, Kent (0342) 410373. **Reference** I. Heine R.J. et al, Diabetologia, 1984; 27: 558-562. \*Registered Trade Mark



*designed for each other.*

**HUMAN VELOSULIN**<sup>®</sup>

Human neutral soluble insulin (emp)

**HUMAN INSULATARD**<sup>®</sup>

Human isophane (NPH) insulin (emp)

**Quick and intermediate acting insulins developed to be compatible.**

**No interaction when mixed.!**

**Predictable effect in individually titrated regimens.**